BioCentury | Feb 10, 2017
Clinical News

CEVA101: Ph I data

...6 cells/kg doses of IV CEVA101 were well tolerated with no serious adverse events reported. Cellvation...
...and adults. Cellvation is a majority-owned subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO, New York, N.Y.). Cellvation Inc....
...and global functioning using the Disability Rating Scale (DRS) Status: Phase I data Milestone: NA Chris Lieu CEVA101 Cellvation Inc....
BioCentury | Nov 24, 1997
Company News

Celox, TaKaRa Shuzo Ltd. deal

...TaKaRa received non-exclusive marketing rights to CELX's Cellvation cell freezing and reconstituting technology. TaKaRa will market...
Items per page:
1 - 2 of 2
BioCentury | Feb 10, 2017
Clinical News

CEVA101: Ph I data

...6 cells/kg doses of IV CEVA101 were well tolerated with no serious adverse events reported. Cellvation...
...and adults. Cellvation is a majority-owned subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO, New York, N.Y.). Cellvation Inc....
...and global functioning using the Disability Rating Scale (DRS) Status: Phase I data Milestone: NA Chris Lieu CEVA101 Cellvation Inc....
BioCentury | Nov 24, 1997
Company News

Celox, TaKaRa Shuzo Ltd. deal

...TaKaRa received non-exclusive marketing rights to CELX's Cellvation cell freezing and reconstituting technology. TaKaRa will market...
Items per page:
1 - 2 of 2